drugset / Trial / NCT02529072
Nivolumab With DC Vaccines for Recurrent Brain Tumors
Phase 1
Completed
6 enrolled
Gary Archer Ph.D.
Bristol-Myers Squibb · collabDuke Cancer Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-09-15
- Completion
- 2019-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC | Cell therapy | — | Other |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |